IL303512A - Therapeutic regimens and methods for lowering blood glucose or body weight using balanced GLP-1R and GCGR agonists - Google Patents

Therapeutic regimens and methods for lowering blood glucose or body weight using balanced GLP-1R and GCGR agonists

Info

Publication number
IL303512A
IL303512A IL303512A IL30351223A IL303512A IL 303512 A IL303512 A IL 303512A IL 303512 A IL303512 A IL 303512A IL 30351223 A IL30351223 A IL 30351223A IL 303512 A IL303512 A IL 303512A
Authority
IL
Israel
Prior art keywords
dose
peptide
alt
glp
day
Prior art date
Application number
IL303512A
Other languages
English (en)
Hebrew (he)
Original Assignee
Spitfire Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spitfire Pharma Llc filed Critical Spitfire Pharma Llc
Publication of IL303512A publication Critical patent/IL303512A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL303512A 2020-12-07 2021-12-07 Therapeutic regimens and methods for lowering blood glucose or body weight using balanced GLP-1R and GCGR agonists IL303512A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063122117P 2020-12-07 2020-12-07
US202163211157P 2021-06-16 2021-06-16
US202163249468P 2021-09-28 2021-09-28
PCT/US2021/062286 WO2022125598A1 (en) 2020-12-07 2021-12-07 Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists

Publications (1)

Publication Number Publication Date
IL303512A true IL303512A (en) 2023-08-01

Family

ID=81972768

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303512A IL303512A (en) 2020-12-07 2021-12-07 Therapeutic regimens and methods for lowering blood glucose or body weight using balanced GLP-1R and GCGR agonists

Country Status (8)

Country Link
US (1) US20250134963A1 (https=)
EP (1) EP4255564A4 (https=)
JP (1) JP2024500324A (https=)
KR (1) KR20230129425A (https=)
CA (1) CA3201539A1 (https=)
IL (1) IL303512A (https=)
MX (1) MX2023006736A (https=)
WO (1) WO2022125598A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240269238A1 (en) * 2022-09-14 2024-08-15 Spitfire Pharma Llc Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
JP2025537192A (ja) * 2022-11-05 2025-11-14 スピットファイア ファーマ エルエルシー Ｇｌｐ－１ｒおよびｇｃｇｒアゴニストを使用した心血管リスク因子の処置のための治療レジメンおよび方法
WO2025098416A1 (zh) * 2023-11-06 2025-05-15 甘李药业股份有限公司 用于减肥的glp-1化合物
WO2025193765A1 (en) * 2024-03-12 2025-09-18 Spitfire Pharma Llc Therapeutic regimens and methods for reducing body weight and/or serum lipids using a glp-1r and gcgr agonist
CN118477048B (zh) * 2024-05-24 2024-12-17 山东泰合医药科技有限公司 一种布瑞哌唑缓释微球及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
PT3155017T (pt) * 2014-05-28 2024-05-14 Mederis Diabetes Llc Farmacêuticos peptídicos melhorados para resistência à insulina
ES2983409T3 (es) * 2016-03-10 2024-10-23 Medimmune Ltd Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica
EP4506017A3 (en) * 2018-01-03 2025-05-14 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
US12441776B2 (en) * 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations

Also Published As

Publication number Publication date
CA3201539A1 (en) 2022-06-16
MX2023006736A (es) 2023-08-21
WO2022125598A1 (en) 2022-06-16
JP2024500324A (ja) 2024-01-09
KR20230129425A (ko) 2023-09-08
EP4255564A4 (en) 2024-11-06
EP4255564A1 (en) 2023-10-11
US20250134963A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
US12257229B2 (en) Peptide pharmaceuticals for treatment of NASH and other disorders
US20250134963A1 (en) Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
US20240148879A1 (en) Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
JP7752619B2 (ja) Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法
US20240269238A1 (en) Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
US12171806B2 (en) Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
US20240277815A1 (en) Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist
HK40101792A (zh) 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
EP4611792A1 (en) Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist
HK40125993A (zh) 使用glp-1r和gcgr激动剂降低患有脂肪性肝病的受试者的体重的治疗方案和方法
HK40127149A (zh) 使用glp-1r和gcgr激动剂治疗心血管风险因素的治疗方案和方法